Published in Curr Pharm Des on January 01, 2014
Modulatory effects of α7 nAChRs on the immune system and its relevance for CNS disorders. Cell Mol Life Sci (2016) 0.88
Addressing Cognitive Deficits in Schizophrenia: Toward a Neurobiologically Informed Approach. Biol Psychiatry (2017) 0.75
Multiple Kinases Involved in the Nicotinic Modulation of Gamma Oscillations in the Rat Hippocampal CA3 Area. Front Cell Neurosci (2017) 0.75
Minimal effects of prolonged smoking abstinence or resumption on cognitive performance challenge the "self-medication" hypothesis in schizophrenia. Schizophr Res (2017) 0.75
Neuroimmune Interactions in Schizophrenia: Focus on Vagus Nerve Stimulation and Activation of the Alpha-7 Nicotinic Acetylcholine Receptor. Front Immunol (2017) 0.75
Updating P300: an integrative theory of P3a and P3b. Clin Neurophysiol (2007) 13.66
Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull (2000) 9.62
The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry (2008) 9.00
Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology (1998) 8.73
Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization. Science (2004) 5.94
A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res (2005) 5.78
Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev (2009) 5.64
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry (2007) 5.64
Identification of separable cognitive factors in schizophrenia. Schizophr Res (2004) 5.34
A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull (2005) 4.66
The functional significance of social cognition in schizophrenia: a review. Schizophr Bull (2006) 4.64
Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry (2004) 4.46
Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Arch Gen Psychiatry (2007) 4.44
Prevalence of smoking among psychiatric outpatients. Am J Psychiatry (1986) 4.32
Early selective-attention effect on evoked potential reinterpreted. Acta Psychol (Amst) (1978) 4.13
The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry (2008) 4.02
Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol (2006) 3.84
Working memory dysfunction in schizophrenia. J Neuropsychiatry Clin Neurosci (1994) 3.77
The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res (2004) 3.57
Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry (2008) 3.13
Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations. J Med Chem (2005) 2.94
Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry (1995) 2.72
Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology (2006) 2.70
Cellular and synaptic mechanisms of nicotine addiction. J Neurobiol (2002) 2.68
Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry (2006) 2.63
Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia. Biol Psychiatry (1982) 2.60
Neuropsychology and neuropharmacology of P3a and P3b. Int J Psychophysiol (2006) 2.57
Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology (Berl) (2010) 2.44
Mismatch negativity in schizophrenia: a meta-analysis. Schizophr Res (2005) 2.41
A computer-administered neurobehavioral evaluation system for occupational and environmental epidemiology. Rationale, methodology, and pilot study results. J Occup Med (1985) 2.35
Neuronal nicotinic receptors in the human brain. Prog Neurobiol (2000) 2.31
Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors h alpha 2 beta 2, h alpha 2 beta 4, h alpha 3 beta 2, h alpha 3 beta 4, h alpha 4 beta 2, h alpha 4 beta 4 and h alpha 7 expressed in Xenopus oocytes. J Pharmacol Exp Ther (1997) 2.30
Meta-analysis of the P300 and P50 waveforms in schizophrenia. Schizophr Res (2004) 2.30
Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. Arch Gen Psychiatry (2005) 2.28
Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry (2003) 2.18
Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology (Berl) (1994) 2.09
The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull (1999) 1.99
Effect of smoking history on [3H]nicotine binding in human postmortem brain. J Pharmacol Exp Ther (1997) 1.98
Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am J Psychiatry (1998) 1.95
Nicotine use in schizophrenia: the self medication hypotheses. Neurosci Biobehav Rev (2005) 1.93
Schizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull (1998) 1.92
Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophr Res (2010) 1.91
The mismatch negativity (MMN): towards the optimal paradigm. Clin Neurophysiol (2004) 1.89
Cognitive deficits as treatment targets in schizophrenia. Schizophr Res (2004) 1.86
Meta-analysis of P300 and schizophrenia: patients, paradigms, and practical implications. Psychophysiology (2003) 1.85
Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia I: sensitivity, reliability, and validity. Am J Psychiatry (1999) 1.81
Sensory gating endophenotype based on its neural oscillatory pattern and heritability estimate. Arch Gen Psychiatry (2008) 1.78
Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther (2003) 1.77
Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology (2000) 1.77
Preliminary validity of "integneuro": a new computerized battery of neurocognitive tests. Int J Neurosci (2005) 1.76
Nicotine induces glutamate release from thalamocortical terminals in prefrontal cortex. Neuropsychopharmacology (2003) 1.74
Ultrastructural distribution of the alpha7 nicotinic acetylcholine receptor subunit in rat hippocampus. J Neurosci (2001) 1.73
Galantamine improves cognition in schizophrenic patients stabilized on risperidone. Biol Psychiatry (2006) 1.73
Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry (2006) 1.69
The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology (2007) 1.67
Schizophrenia and the alpha7 nicotinic acetylcholine receptor. Int Rev Neurobiol (2007) 1.65
Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry (1997) 1.64
Nicotine effects on brain function and functional connectivity in schizophrenia. Biol Psychiatry (2004) 1.64
Smoking and mental illness. Pharmacol Biochem Behav (2001) 1.63
Alpha7 neuronal nicotinic receptors as a drug target in schizophrenia. Expert Opin Ther Targets (2012) 1.63
Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology (1996) 1.62
Frontal-striatal cognitive deficits in patients with chronic schizophrenia. Brain (1997) 1.61
The MATRICS initiative: developing a consensus cognitive battery for clinical trials. Schizophr Res (2004) 1.59
A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry (2002) 1.59
Psychometric comparison of computerized and standard administration of the neurocognitive assessment instruments selected by the CATIE and MATRICS consortia among patients with schizophrenia. Schizophr Res (2007) 1.55
Effects of nicotine nasal spray on cognitive function in schizophrenia. Neuropsychopharmacology (2006) 1.55
beta2-Nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking. Arch Gen Psychiatry (2009) 1.53
A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry (2012) 1.52
P50 sensory gating ratios in schizophrenics and controls: a review and data analysis. Psychiatry Res (2008) 1.52
Impaired mismatch negativity generation reflects widespread dysfunction of working memory in schizophrenia. Arch Gen Psychiatry (1995) 1.49
Genetics of nicotinic acetylcholine receptors: Relevance to nicotine addiction. Biochem Pharmacol (2007) 1.49
Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients. Am J Psychiatry (2004) 1.49
Defining a cognitive function decrement in schizophrenia. Biol Psychiatry (2005) 1.47
The relationship of neuropsychological abilities to specific domains of functional capacity in older schizophrenia patients. Biol Psychiatry (2003) 1.46
Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport (1995) 1.46
Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia. Biol Psychiatry (2010) 1.45
Evolution of neuropsychological dysfunction during the course of schizophrenia and bipolar disorder. Psychol Med (2010) 1.43
Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry (2007) 1.39
Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. Neuroreport (1999) 1.38
Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology (2002) 1.37
Effects of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacology (2004) 1.37
The association between high nicotine dependence and severe mental illness may be consistent across countries. J Clin Psychiatry (2002) 1.34
A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology (2012) 1.33
Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. Arch Gen Psychiatry (2011) 1.33
Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: alpha-bungarotoxin and nicotine binding in the thalamus. J Neurochem (1999) 1.33
Mismatch negativity--a unique measure of sensory processing in audition. Int J Neurosci (1995) 1.32
Nicotine and behavioral markers of risk for schizophrenia: a double-blind, placebo-controlled, cross-over study. Neuropsychopharmacology (2002) 1.32
Sensory gating in schizophrenia: P50 and N100 gating in antipsychotic-free subjects at risk, first-episode, and chronic patients. Biol Psychiatry (2008) 1.31
Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). Schizophr Res (2008) 1.30
Brain potential evidence for an auditory sensory memory deficit in schizophrenia. Am J Psychiatry (1995) 1.29
Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology (2007) 1.27
Impaired mismatch negativity (MMN) generation in schizophrenia as a function of stimulus deviance, probability, and interstimulus/interdeviant interval. Electroencephalogr Clin Neurophysiol (1998) 1.27
Review on vocational predictors: a systematic review of predictors of vocational outcomes among individuals with schizophrenia: an update since 1998. Aust N Z J Psychiatry (2010) 1.26
Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. Schizophr Bull (2003) 1.24
Neurometabolites in schizophrenia and bipolar disorder - a systematic review and meta-analysis. Psychiatry Res (2012) 1.23
Schizophrenia and nicotine use: report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophr Bull (1997) 1.21
Central auditory dysfunction in schizophrenia as revealed by the mismatch negativity (MMN) and its magnetic equivalent MMNm: a review. Int J Neuropsychopharmacol (2008) 1.21
Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull (2007) 1.21
Systemic hypotheses for generalized cognitive deficits in schizophrenia: a new take on an old problem. Schizophr Bull (2008) 1.21
Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia. J Chem Neuroanat (2001) 1.20
Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psychiatry (2004) 6.05
The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull (2009) 4.69
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov (2008) 4.46
Social supports and serotonin transporter gene moderate depression in maltreated children. Proc Natl Acad Sci U S A (2004) 4.42
Brain-derived neurotrophic factor-5-HTTLPR gene interactions and environmental modifiers of depression in children. Biol Psychiatry (2006) 3.97
Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry (2004) 3.64
Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med (2011) 3.36
A prospective cohort study investigating factors associated with depression during medical internship. Arch Gen Psychiatry (2010) 2.41
The role of default network deactivation in cognition and disease. Trends Cogn Sci (2012) 2.39
A functional magnetic resonance imaging study of bipolar disorder: state- and trait-related dysfunction in ventral prefrontal cortices. Arch Gen Psychiatry (2003) 2.36
Effects of smoking and smoking abstinence on cognition in adolescent tobacco smokers. Biol Psychiatry (2005) 2.36
Association between alcoholism and gamma-amino butyric acid alpha2 receptor subtype in a Russian population. Alcohol Clin Exp Res (2005) 2.35
A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry (2008) 2.17
Individuals family history positive for alcoholism show functional magnetic resonance imaging differences in reward sensitivity that are related to impulsivity factors. Biol Psychiatry (2010) 2.16
Amygdala and hippocampal volumes in adolescents and adults with bipolar disorder. Arch Gen Psychiatry (2003) 2.15
Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia. J Clin Psychiatry (2012) 2.10
Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry (2009) 2.09
Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study. Arch Gen Psychiatry (2002) 2.01
Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry (2002) 1.99
Altered NMDA glutamate receptor antagonist response in individuals with a family vulnerability to alcoholism. Am J Psychiatry (2004) 1.96
Cigarette smoking and mortality risk in people with schizophrenia. Schizophr Bull (2009) 1.95
Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. Alcohol Clin Exp Res (2007) 1.86
Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative. Biol Psychiatry (2008) 1.81
Transcranial magnetic stimulation of left temporoparietal cortex and medication-resistant auditory hallucinations. Arch Gen Psychiatry (2003) 1.81
The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res (2011) 1.80
Rare nonsynonymous variants in alpha-4 nicotinic acetylcholine receptor gene protect against nicotine dependence. Biol Psychiatry (2011) 1.76
Impairment of working memory maintenance and response in schizophrenia: functional magnetic resonance imaging evidence. Biol Psychiatry (2008) 1.76
Abnormal hemodynamics in schizophrenia during an auditory oddball task. Biol Psychiatry (2005) 1.72
Frontostriatal abnormalities in adolescents with bipolar disorder: preliminary observations from functional MRI. Am J Psychiatry (2003) 1.70
Impaired visual cortical plasticity in schizophrenia. Biol Psychiatry (2012) 1.67
Preliminary evidence for medication effects on functional abnormalities in the amygdala and anterior cingulate in bipolar disorder. Psychopharmacology (Berl) (2005) 1.67
Rare ADH variant constellations are specific for alcohol dependence. Alcohol Alcohol (2012) 1.66
Increased cortical GABA concentrations in depressed patients receiving ECT. Am J Psychiatry (2003) 1.64
Nicotine effects on brain function and functional connectivity in schizophrenia. Biol Psychiatry (2004) 1.64
Global prefrontal and fronto-amygdala dysconnectivity in bipolar I disorder with psychosis history. Biol Psychiatry (2012) 1.62
Ketamine and the potential role for rapid-acting antidepressant medications. Swiss Med Wkly (2007) 1.62
Genetic and environmental predictors of early alcohol use. Biol Psychiatry (2006) 1.60
Extracellular metabolites in the cortex and hippocampus of epileptic patients. Ann Neurol (2005) 1.55
Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biol Psychiatry (2005) 1.55
Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry (2005) 1.52
Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meeting. Schizophr Bull (2008) 1.52
Glutamate metabolism in major depressive disorder. Am J Psychiatry (2014) 1.52
Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry (2006) 1.51
Capturing the angel in "angel dust": twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans. Schizophr Bull (2012) 1.50
Genome-wide association study of alcohol dependence implicates KIAA0040 on chromosome 1q. Neuropsychopharmacology (2011) 1.50
Striking differences in glucose and lactate levels between brain extracellular fluid and plasma in conscious human subjects: effects of hyperglycemia and hypoglycemia. J Cereb Blood Flow Metab (2002) 1.48
Age, rapid-cycling, and pharmacotherapy effects on ventral prefrontal cortex in bipolar disorder: a cross-sectional study. Biol Psychiatry (2006) 1.47
Preliminary evidence for persistent abnormalities in amygdala volumes in adolescents and young adults with bipolar disorder. Bipolar Disord (2005) 1.47
Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx (2006) 1.43
Corpus callosum in maltreated children with posttraumatic stress disorder: a diffusion tensor imaging study. Psychiatry Res (2008) 1.42
Family history of alcoholism influences naltrexone-induced reduction in alcohol drinking. Biol Psychiatry (2007) 1.42
Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. Annu Rev Med (2014) 1.39
Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers. Drug Alcohol Depend (2010) 1.39
Clinical studies implementing glutamate neurotransmission in mood disorders. Ann N Y Acad Sci (2003) 1.35
Effects of NMDA receptor antagonists: implications for the pathophysiology of schizophrenia. Arch Gen Psychiatry (2002) 1.34
Probing the pathophysiology of auditory/verbal hallucinations by combining functional magnetic resonance imaging and transcranial magnetic stimulation. Cereb Cortex (2007) 1.34
Glutamatergic model psychoses: prediction error, learning, and inference. Neuropsychopharmacology (2010) 1.34
Sex, GABA, and nicotine: the impact of smoking on cortical GABA levels across the menstrual cycle as measured with proton magnetic resonance spectroscopy. Biol Psychiatry (2005) 1.33
Sex differences in striatal dopamine release in young adults after oral alcohol challenge: a positron emission tomography imaging study with [¹¹C]raclopride. Biol Psychiatry (2010) 1.33
MAOA genotype, maltreatment, and aggressive behavior: the changing impact of genotype at varying levels of trauma. Biol Psychiatry (2008) 1.32
NMDA receptor function in large-scale anticorrelated neural systems with implications for cognition and schizophrenia. Proc Natl Acad Sci U S A (2012) 1.32
N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology (Berl) (2005) 1.31
Neural synchrony in schizophrenia: from networks to new treatments. Schizophr Bull (2007) 1.28
Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia II: developing imaging biomarkers to enhance treatment development for schizophrenia and related disorders. Biol Psychiatry (2011) 1.26
The NMDA receptor as a therapeutic target in major depressive disorder. CNS Neurol Disord Drug Targets (2007) 1.25
Riluzole in the treatment of mood and anxiety disorders. CNS Drugs (2008) 1.24
Significance of adolescent neurodevelopment for the neural circuitry of bipolar disorder. Ann N Y Acad Sci (2004) 1.23
Psychiatric safety of ketamine in psychopharmacology research. Psychopharmacology (Berl) (2007) 1.22
Why do delusions persist? Front Hum Neurosci (2009) 1.20
Glutamatergic modulation of auditory information processing in the human brain. Biol Psychiatry (2011) 1.20
Impaired GABA neuronal response to acute benzodiazepine administration in panic disorder. Am J Psychiatry (2004) 1.20
A novel, functional and replicable risk gene region for alcohol dependence identified by genome-wide association study. PLoS One (2011) 1.19
Effect of memantine on cue-induced alcohol craving in recovering alcohol-dependent patients. Am J Psychiatry (2007) 1.17
Yohimbine-induced withdrawal and anxiety symptoms in opioid-dependent patients. Biol Psychiatry (2002) 1.16
Trajectories of depression severity in clinical trials of duloxetine: insights into antidepressant and placebo responses. Arch Gen Psychiatry (2011) 1.16
Naltrexone and combined behavioral intervention effects on trajectories of drinking in the COMBINE study. Drug Alcohol Depend (2009) 1.16
Association of posttraumatic stress disorder with reduced in vivo norepinephrine transporter availability in the locus coeruleus. JAMA Psychiatry (2013) 1.14
Fore-period effect and stop-signal reaction time. Exp Brain Res (2005) 1.13
New insights into the efficacy of naltrexone based on trajectory-based reanalyses of two negative clinical trials. Biol Psychiatry (2007) 1.12
Decreased hippocampal volume on MRI is associated with increased extracellular glutamate in epilepsy patients. Epilepsia (2008) 1.11
Impact of intravenous nicotine on BOLD signal response to photic stimulation. Magn Reson Imaging (2002) 1.11
GABA and glutamate systems as therapeutic targets in depression and mood disorders. Expert Opin Ther Targets (2005) 1.10
Glutamatergic targets for new alcohol medications. Psychopharmacology (Berl) (2013) 1.10
Cortical gamma-aminobutyric acid levels and the recovery from ethanol dependence: preliminary evidence of modification by cigarette smoking. Biol Psychiatry (2005) 1.10
Linking microcircuit dysfunction to cognitive impairment: effects of disinhibition associated with schizophrenia in a cortical working memory model. Cereb Cortex (2012) 1.09
Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study. J Clin Psychopharmacol (2011) 1.08
Preliminary evidence of reduced occipital GABA concentrations in puerperal women: a 1H-MRS study. Psychopharmacology (Berl) (2006) 1.06
Effects of ketamine in treatment-refractory obsessive-compulsive disorder. Biol Psychiatry (2012) 1.06
Multidimensionality of the Alcohol Withdrawal Symptom Checklist: a factor analysis of the Alcohol Withdrawal Symptom Checklist and CIWA-Ar. Alcohol Clin Exp Res (2007) 1.05
Intravenous ethanol infusion decreases human cortical γ-aminobutyric acid and N-acetylaspartate as measured with proton magnetic resonance spectroscopy at 4 tesla. Biol Psychiatry (2011) 1.04
Ketamine as a promising prototype for a new generation of rapid-acting antidepressants. Ann N Y Acad Sci (2015) 1.04
Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. Alcohol Clin Exp Res (2007) 1.03
Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy: a [(123)I]CNS-1261 SPET study. Psychopharmacology (Berl) (2008) 1.03
The impact of NMDA receptor blockade on human working memory-related prefrontal function and connectivity. Neuropsychopharmacology (2013) 1.02
Neural correlates of impulsivity in healthy males and females with family histories of alcoholism. Neuropsychopharmacology (2013) 1.02
Dimensional structure of DSM-5 posttraumatic stress disorder symptoms: results from the National Health and Resilience in Veterans Study. J Clin Psychiatry (2015) 1.02
Serotonin 1B receptor imaging in alcohol dependence. Biol Psychiatry (2010) 1.02
Frontotemporal neural systems in bipolar disorder. Semin Clin Neuropsychiatry (2002) 1.01
A broken filter: prefrontal functional connectivity abnormalities in schizophrenia during working memory interference. Schizophr Res (2012) 1.01
Noradrenergic vs serotonergic antidepressant with or without naltrexone for veterans with PTSD and comorbid alcohol dependence. Neuropsychopharmacology (2011) 1.00